Insider Transactions Reported | Sight Sciences(SGHT)saw insider trading activity on 6/3/2025

Sight Sciences(SGHT) saw insider trading activity on 6/3/2025, there were 3 insider trades during the day.

【History Insider Transaction】

Declare date	Position	Name	Buy/Sell	Quantity	Price per share/USD	Total Amount/USD
6/3/2025	--	Encrantz Staffan	Buy	25230	3.97	100.09k
6/3/2025	--	Encrantz Staffan	Buy	42753	3.67	156.9k
6/3/2025	--	Encrantz Staffan	Buy	30799	3.88	119.44k
5/29/2025	--	Encrantz Staffan	Buy	26715	3.52	93.93k
5/29/2025	--	Encrantz Staffan	Buy	41346	3.44	142.06k
5/29/2025	--	Encrantz Staffan	Buy	60128	3.59	215.74k
5/21/2025	Chief Financial Officer	Bauerlein Alison	Sell	13066	3.48	45.43k
5/21/2025	Chief Commercial Officer	Link Matthew	Buy	6631	3.02	20.01k
5/21/2025	EVP, Research & Development	Raheja Manohar K.	Buy	12767	3.02	38.53k
4/3/2025	President and CEO	Badawi Paul	Sell	24174	2.30	55.67k

[Company Profile]
Sight Sciences, Inc., was incorporated in Delaware in February 2010. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and non-surgical technologies for the treatment of common eye diseases. The company's business philosophy is based on the following principles: a comprehensive understanding of disease physiology; the development of transformative technologies designed to protect, protect and restore the natural physiological functions of diseased eyes; the development and marketing of products with proven clinical evidence that achieve effectiveness over current treatment models while minimizing complications or side effects; and the provision of intuitive, patient-friendly interventional solutions for ophthalmologists and optometrists; And provide compelling economic value to all stakeholders, including patients, providers and third-party payers such as health insurance companies and commercial insurance companies.